Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften
DAK-Gesundheit awarded €1 to Galderma Laboratorium GmbH for Healthcare & Medical in June 2025 — one of 389 awards this buyer has made, in line with its typical award size.
Buying agency
DAK-GesundheitWinning supplier
Galderma Laboratorium GmbHContract description
Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften Sozialgesetzbuchs - Nemluvio (Wirkstoff: Nemolizumab), ATC D11AH12
Related awards · DAK-Gesundheit
389 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-210283-2024Aktivital GmbH€9.1M10 Apr 2024 Healthcare
- ocds-ted-211590-2024Kraaibeek GmbH€2.5M10 Apr 2024 Healthcare
- ocds-ted-828775-2025news aktuell GmbH€38.0K12 Dec 2025 IT
Other wins · Galderma Laboratorium GmbH
2 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-1003-2026IKK classic€102 Jan 2026 Healthcare
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for DAK-Gesundheit and Galderma Laboratorium GmbH — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back